FIELD: biotechnology.
SUBSTANCE: present invention relates to immunology and biotechnology. Proposed is a host cell expressing a human IgG1 antibody and an antibody produced by expression of nucleic acids in such a cell that specifically binds to IL-1α.
EFFECT: present invention can be used for treating, preventing or detecting the pathology associated with aberrant expression of IL-1α.
7 cl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO INTERLEUKIN-1α, AND ITS APPLICATION METHODS | 2009 |
|
RU2498998C2 |
| TREATING VASCULAR DISEASE AND COMPLICATIONS THEREOF | 2013 |
|
RU2671955C2 |
| RECOMBINANT ANTIBODY IL4 USED FOR TREATMENT OF DISORDERS ASSOCIATED WITH FUNCTION OF IL4 | 1994 |
|
RU2162711C2 |
| ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
| CACHEXIA THERAPY | 2012 |
|
RU2622021C2 |
| TREATMENT OF NEOPLASTIC DISEASES | 2011 |
|
RU2679119C2 |
| TREATING OSTEOARTHRITIS AND PAIN | 2012 |
|
RU2563830C2 |
| ANTIBODIES SPECIFIC TO BTN2 AND THEIR APPLICATIONS | 2018 |
|
RU2794996C2 |
| IL-13 RECEPTOR ALPHA 1 ANTIBODIES AND THEIR APPLICATION | 2006 |
|
RU2413736C2 |
| IMMUNOGLOBULINS | 2005 |
|
RU2404192C2 |
